View all news

Nevro Reports First Quarter 2018 Financial Results

May 7, 2018

REDWOOD CITY, Calif., May 7, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2018.

First Quarter Highlights:

  • Achieved revenue of $87.6 million in the first quarter of 2018, an increase of 28% as reported, over the same period of the prior year
    • U.S. revenue of $70.6 million in the first quarter of 2018, an increase of 33% over the prior year
    • International revenue of $17.0 million in the first quarter of 2018, an increase of 1% in constant currency and 11% on an as-reported basis, both over the same period of the prior year
  • Received U.S. Food & Drug Administration (FDA) approval for the Senza II™ Spinal Cord Stimulation (SCS) System
  • Announced full-body magnetic resonance imaging (MRI) conditional labeling in the U.S. for the Senza SCS System
  • Presented on clinical and scientific progress at the 2018 North American Neuromodulation Society (NANS) meeting

First Quarter Financial Results

Revenue for the three months ended March 31, 2018 was $87.6 million versus $68.4 million during the same period of the prior year, representing 28% growth as reported. U.S. revenue for the three months ended March 31, 2018 was $70.6 million, representing 33% growth as reported. International revenue was $17.0 million, representing growth of 1% in constant currency and 11% on an as-reported basis. The increase in revenue was primarily attributable to the continued adoption of the Senza system.

Gross profit for the three months ended March 31, 2018 was $62.0 million, representing a 71% gross margin, up from $46.4 million, representing a 68% gross margin, in the same period of the prior year.

Operating expenses for the three months ended March 31, 2018 were $77.7 million compared to $59.4 million in the same period of the prior year, representing an increase of 31%. The increase in operating expenses was driven primarily by increased headcount and related personnel costs, as well as legal expenses associated with intellectual property litigations.

Loss from operations for the first quarter of 2018 was $15.7 million compared to $13.1 million for the same period of the prior year.

Revenue Guidance for Full Year 2018

Nevro reiterates its expectations for worldwide revenue for 2018 to be in the range of $400 to $410 million.

Webcast and Conference Call Information

Management will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers, or (734) 385-2616 for international callers (Conference ID: 8882719), or from the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The Senza® System and Senza II™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

Forward-Looking Statements

In addition to historical information, this press release contains forward-looking statements with respect to our business, capital resources, revenue projections, strategic initiatives and growth, reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including continuing adoption of, and interest in, Senza in the U.S. and international markets and our expectations for worldwide revenue for the full year 2018. These forward-looking statements are based upon information that is currently available to us or our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including our ability to successfully commercialize our products; our ability to manufacture our products to meet demand; the level and availability of third-party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These factors, together with those that are described in greater detail in our Annual Report on Form 10-K filed on February 22, 2018 and our Quarterly Report on Form 10-Q that we expect to file on May 7, 2018, as well as any reports that we may file with the SEC in the future, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements. Our results for the quarter ended March 31, 2018 are not necessarily indicative of our operating results for any future periods.

Investor Relations Contact:
Nevro Investor Relations
Katherine Bock
(650) 433-3247
ir@nevro.com

Nevro Corp.

Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)







Three Months Ended




March 31,




2018



2017













(unaudited)


Revenue


$

87,635



$

68,439


Cost of revenue



25,634




22,071


Gross profit



62,001




46,368


Operating expenses:









Research and development



11,085




8,699


Sales, general and administrative



66,618




50,720


Total operating expenses



77,703




59,419


Loss from operations



(15,702)




(13,051)


Other income (expense):









Interest income (expense), net



(1,545)




(1,726)


Other income (expense), net



(123)




531


Loss before income taxes



(17,370)




(14,246)


Provision for income taxes



343




261


Net loss



(17,713)




(14,507)


Changes in foreign currency translation adjustment



577




(222)


Changes in unrealized gains (losses) on short-term investments



(351)




44


Net change in other comprehensive loss



226




(178)


Comprehensive Loss


$

(17,487)



$

(14,685)


Net loss per share, basic and diluted


$

(0.59)



$

(0.50)


Weighted average shares used to compute net loss per share, basic and diluted



29,836,277




29,159,509


 

Nevro Corp.

Consolidated Balance Sheets

(in thousands, except share and per share data)










March 31,



December 31,




2018



2017




(unaudited)






Assets









Current assets









Cash and cash equivalents


$

27,650



$

42,845


Short-term investments



231,960




226,467


Accounts receivable, net



62,664




67,287


Inventories, net



97,497




98,119


Prepaid expenses and other current assets



7,751




6,463


Total current assets



427,522




441,181


Property and equipment, net



12,773




8,819


Other assets



3,744




3,250


Restricted cash



806




806


Total assets


$

444,845



$

454,056


Liabilities and stockholders' equity









Current liabilities









Accounts payable


$

22,224



$

18,492


Accrued liabilities and other



31,273




39,512


Total current liabilities



53,497




58,004


Long-term debt



146,821




145,019


Other long-term liabilities



1,905




1,861


Total liabilities



202,223




204,884


Stockholders' equity









Common stock, $0.001 par value, 290,000,000 shares authorized, 29,943,768 and 29,737,561 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively



30




30


Additional paid-in capital



518,198




508,228


Accumulated other comprehensive loss



(1,016)




(1,242)


Accumulated deficit



(274,590)




(257,844)


Total stockholders' equity



242,622




249,172


Total liabilities and stockholders' equity


$

444,845



$

454,056


 

.

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/nevro-reports-first-quarter-2018-financial-results-300643742.html

SOURCE Nevro Corp.

Multimedia Files:

View all news